Adebrelimab plus standard care for pancreatic cancer with fluid buildup
Treatments studied
Part of Cancer clinical trials.
This trial tests adding the drug Adebrelimab to standard care for people with pancreatic cancer that has caused fluid buildup around the lungs or in the belly (called pleural or peritoneal effusions). The goal is to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with a confirmed diagnosis of pancreatic cancer.
- You must have fluid buildup around the lungs or in the belly that is at least 4 cm deep and needs treatment.
- You must have at least one tumor that can be measured on scans.
- You need to be well enough to care for yourself (ECOG score 0-3) and have an expected survival of at least 2 months.
- Your liver, kidney, and blood cell counts must meet certain minimum levels.
- You must not have conditions that prevent immunotherapy, such as uncontrolled autoimmune disease or active infections like HIV or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery for pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Hear when a new Pancreatic Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.